- Home
- Automated
- List of product information
- EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V [SIN16951P]
EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V [SIN16951P]
Active ingredients: EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V
Last updated 26 October 2025
Product Info
EYBELIS-S OPHTHALMIC SOLUTION 0.002%W/V
[SIN16951P]
Product information
Active Ingredient and Strength | OMIDENEPAG ISOPROPYL - 0.02 MG/ML |
Dosage Form | SOLUTION, STERILE |
Manufacturer and Country | SANTEN PHARMACEUTICAL CO., LTD. NOTO PLANT - JAPAN |
Registration Number | SIN16951P |
Licence Holder | SANTEN PHARMACEUTICAL ASIA PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | S01EX06 |
Therapeutic indications
Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension
Posology and method of administration
Posology
The recommended dose is one drop in the affected eye(s) once daily in the evening.
If a dose is missed, treatment should be continued with the next dose as planned. The dose should not exceed one drop in the affected eye(s) daily.
Paediatric population
The safety and efficacy of omidenepag isopropyl in children and adolescents have not yet been established. No data are available.
Method of administration
For ocular use.
Be careful not to touch the tip of the container to the eye directly in order to avoid the contamination of the drug.
If more than one topical ophthalmic product is being used, each one should be administered at least 5 minutes apart.
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in ‘Description’ – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
Patients with aphakic eyes or intraocular lens (IOL) inserted eyes (see ‘Undesirable effects’ – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Concomitant use with tafluprost (see ‘Interactions’ – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).